Please find enclosed herewith the copy of intimation wrt outcome of meeting of the Board of Directors held today, i.e. May 15, 2026.
OMAXE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.4 pts less than its Residential Commercial Projects peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Omaxe Ltd's Board approved audited financial results for Q4 and FY ended March 31, 2026. On standalone basis, revenue grew 16.4% to Rs 453.64 Cr but the company reported a net loss of Rs 195.61 Cr (vs loss of Rs 217.03 Cr in FY25). On consolidated basis, revenue declined 19.7% to Rs 1,253.40 Cr from Rs 1,560.99 Cr, with net loss widening to Rs 696.80 Cr (vs Rs 685.40 Cr). Finance costs increased significantly to Rs 255.11 Cr on consolidated basis. Statutory auditors issued unmodified (clean) opinions on both standalone and consolidated results. The auditors drew an Emphasis of Matter regarding an ongoing SEBI order from July 2024 under sections 11/11B of SEBI Act, with SAT having granted a partial stay; next hearing is on July 7, 2026. The company also changed its internal auditor from Doogar & Associates to Aditiya Agrawal & Company for FY27.
The significant consolidated revenue decline of ~20% and large net losses (Rs 696.80 Cr consolidated loss) indicate severe financial stress. The SEBI regulatory matter, though management claims no impact, adds uncertainty. Shareholders should monitor the company's ability to service debt and fund operations given negative other equity of Rs 1,084.42 Cr on standalone basis.